Human equilibrative nucleoside transporter 1 expression is a strong independent prognostic factor in UICC T3–T4 pancreatic cancer patients treated with preoperative gemcitabine-based chemoradiotherapy

Background/purposeWe aimed to determine the relationship between the intratumoral expression of human equilibrative nucleoside transporter (hENT1), the main gemcitabine transporter into cells, and the outcome of gemcitabine-based chemoradiotherapy (Gem-CRT) in patients with International Union Against Cancer (UICC) T3–T4 pancreatic adenocarcinoma.MethodsThe expressions of hENT1, thymidylate synthase (TS), and dihydropyrimidine dehydrogenase were immunohistochemically analyzed using the resected specimens from 55 patients (T3, 38 and T4, 17) who had received curative-intent resection after Gem-CRT.ResultsThe status of hENT1 expression (positive in 39 and negative in 16) was significantly associated with “clinical efficacy” (defined as more than 50% reduction of the serum carbohydrate antigen [CA] 19-9 level with stable disease [SD] or partial response [PR] according to the Response Evaluation Criteria in Solid Tumors [RECIST]) for Gem-CRT. The 1- and 3-year overall survival (OS) rates were significantly higher in the positive hENT1 expression group (82.9, 39.5%) than in the negative expression group (42.9, 14.3%) (p = 0.0037). According to combination analysis of hENT1 and TS expressions, the 1- and 3-year OS rates were significantly higher in the positive-low combination (89.1, 51.0%) group than in the negative-high group (66.7, 0%) (p = 0.023). Multivariate analysis revealed that positive hENT1 expression and R0 resection were significant prognostic factors for OS.ConclusionsThe hENT1 expression in pancreatic adenocarcinoma strongly influences the outcome of preoperative Gem-CRT treatment. This biomarker could become a useful predictor of therapeutic effect for gemcitabine-based therapy in pancreatic cancer patients.

[1]  N. Fuchsjäger.  [Results of partial pancreaticoduodenectomy]. , 1973, Wiener klinische Wochenschrift.

[2]  F. Ames,et al.  Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. , 1992, Archives of surgery.

[3]  G. Milano,et al.  Dihydropyrimidine dehydrogenase: a tumoral target for fluorouracil modulation. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[4]  A rationale for expanding the endpoints for clinical trials in advanced pancreatic carcinoma , 1996, Cancer.

[5]  C. Willett,et al.  CA 19-9 is an index of response to neoadjunctive chemoradiation therapy in pancreatic cancer. , 1996, American journal of surgery.

[6]  T. Lawrence,et al.  Radiosensitization of pancreatic cancer cells by 2',2'-difluoro-2'-deoxycytidine. , 1996, International journal of radiation oncology, biology, physics.

[7]  D. V. Von Hoff,et al.  Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  C. R. Crawford,et al.  Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. , 1998, Cancer research.

[9]  V. Grégoire,et al.  Chemo-radiotherapy: radiosensitizing nucleoside analogues (review). , 1999, Oncology reports.

[10]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[11]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.

[12]  I Ihse,et al.  Influence of Resection Margins on Survival for Patients With Pancreatic Cancer Treated by Adjuvant Chemoradiation and/or Chemotherapy in the ESPAC-1 Randomized Controlled Trial , 2001, Annals of surgery.

[13]  J. Mackey,et al.  Immunohistochemical variation of human equilibrative nucleoside transporter 1 protein in primary breast cancers. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[14]  J. Hainsworth,et al.  Irinotecan plus gemcitabine induces both radiographic and CA 19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  E. Saad,et al.  Pretreatment CA 19-9 level as a prognostic factor in patients with advanced pancreatic cancer treated with gemcitabine , 2002, International journal of gastrointestinal cancer.

[16]  A. Mazo,et al.  Nucleoside transporter profiles in human pancreatic cancer cells: role of hCNT1 in 2',2'-difluorodeoxycytidine- induced cytotoxicity. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[17]  H. Pitt,et al.  Thymidylate synthase expression predicts the response to 5-fluorouracil-based adjuvant therapy in pancreatic cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[18]  D. Lorenz,et al.  Long-term Results of Partial Pancreaticoduodenectomy for Ductal Adenocarcinoma of the Pancreatic Head: 25-Year Experience , 2003, World Journal of Surgery.

[19]  John R. Mackey,et al.  The Absence of Human Equilibrative Nucleoside Transporter 1 Is Associated with Reduced Survival in Patients With Gemcitabine-Treated Pancreas Adenocarcinoma , 2004, Clinical Cancer Research.

[20]  A. Nakao,et al.  Clinical Significance of Dihydropyrimidine Dehydrogenase in Adjuvant 5-Fluorouracil Liver Perfusion Chemotherapy for Pancreatic Cancer , 2004, Annals of surgery.

[21]  K. Muro,et al.  Prognostic significance of thymidylate synthase in patients with metastatic colorectal cancer who receive protracted venous infusions of 5-fluorouracil , 2004, International Journal of Clinical Oncology.

[22]  K. Inada,et al.  Immunohistochemical evaluation of thymidylate synthase (TS) and p16INK4a in advanced colorectal cancer: implication of TS expression in 5-FU-based adjuvant chemotherapy. , 2004, Japanese journal of clinical oncology.

[23]  M. Ochiai,et al.  Immunohistochemical demonstration of fluoropyrimidine-metabolizing enzymes in various types of cancer. , 2005, Oncology reports.

[24]  Jeffrey E. Lee,et al.  Borderline Resectable Pancreatic Cancer: Definitions, Management, and Role of Preoperative Therapy , 2006, Annals of Surgical Oncology.

[25]  M. Kornmann,et al.  Thymidylate synthase expression in resectable and unresectable pancreatic cancer: role as predictive or prognostic marker? , 2006, International Journal of Colorectal Disease.

[26]  Franco Mosca,et al.  Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. , 2006, Cancer research.

[27]  P. Philip,et al.  A Multi-Institutional Phase II Trial of Preoperative Full-Dose Gemcitabine and Concurrent Radiation for Patients With Potentially Resectable Pancreatic Carcinoma , 2006, Annals of Surgical Oncology.

[28]  J. Yu,et al.  A margin-negative R0 resection accomplished with minimal postoperative complications is the surgeon’s contribution to long-term survival in pancreatic cancer , 2006, Journal of Gastrointestinal Surgery.

[29]  F. Itokawa,et al.  Ribonucleotide reductase subunit M2 mRNA expression in pretreatment biopsies obtained from unresectable pancreatic carcinomas , 2007, Journal of Gastroenterology.

[30]  Peter Neuhaus,et al.  Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. , 2007, JAMA.

[31]  Takashi Ishikawa,et al.  Human equilibrative nucleoside transporter 1 is associated with the chemosensitivity of gemcitabine in human pancreatic adenocarcinoma and biliary tract carcinoma cells. , 2007, Oncology reports.

[32]  R. Ueda,et al.  The absence of human equilibrative nucleoside transporter 1 expression predicts nonresponse to gemcitabine-containing chemotherapy in non-small cell lung cancer. , 2007, Cancer letters.

[33]  R. Abrams,et al.  Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. , 2008, JAMA.

[34]  H. Oettle,et al.  CONKO-001: Final results of the randomized, prospective, multicenter phase III trial of adjuvant chemotherapy with gemcitabine versus observation in patients with resected pancreatic cancer (PC) , 2008 .

[35]  Jeffrey E. Lee,et al.  Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  Adam P Dicker,et al.  Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. , 2009, Gastroenterology.

[37]  H. Eguchi,et al.  Feasibility and Efficacy of Combination Therapy With Preoperative Full-Dose Gemcitabine, Concurrent Three-Dimensional Conformal Radiation, Surgery, and Postoperative Liver Perfusion Chemotherapy for T3-Pancreatic Cancer , 2009, Annals of surgery.

[38]  T. Hwang,et al.  Expression of thymidylate synthase determines the response of gastric cancer patients undergoing gastrectomy to 5-fluorouracil-based adjuvant chemotherapy , 2010, Langenbeck's Archives of Surgery.

[39]  John R. Mackey,et al.  Human Equilibrative Nucleoside Transporter 1 and Human Concentrative Nucleoside Transporter 3 Predict Survival after Adjuvant Gemcitabine Therapy in Resected Pancreatic Adenocarcinoma , 2009, Clinical Cancer Research.

[40]  Impact of S-1 on the Survival of Patients With Advanced Pancreatic Cancer , 2010, Pancreas.

[41]  H. Tomita,et al.  Contribution of Thymidylate Synthase to Gemcitabine Therapy for Advanced Pancreatic Cancer , 2010, Pancreas.